摘要
目的探讨^18F—FDGPET(PET/CT)在原发性肾上腺淋巴瘤(PAL)中的作用。方法回顾性分析2005年10月至2009年8月确诊为PAL的3例患者。3例均为老年男性,双侧性NHL,治疗前均行超声、CT及PET(PET/CT)检查,并有组织病理学诊断资料。采用利妥昔单抗(rituximab)与环磷酰胺(cyclophosphamide)、表阿霉素(doxorubicin)、长春新碱(vincristine)、泼尼松(prednisone)组合(R—CHOP)方案化疗。治疗后1例进行了PET/CT的随访复查。^18F—FDGPET显像获得病灶SUVmax及与肝SUVmax的比值。结果3例均为双侧性弥漫大B细胞型PAL,骨髓穿刺阴性,R-CHOP方案化疗后,例1通过4次^18F—FDGPET复查随访、指导治疗,已存活1年7个月;例2伴有肾上腺皮质功能低下,6个月后死亡;例3年龄大(77岁),病情重,手术部分切除后化疗,12个月后死亡。结论PAL虽然恶性程度极高,但如能早期诊断,并进行^18F—FDGPET疗效监测、修正治疗方案,可延长患者生存期。
Objective To evaluate 18F-FDG PET/CT imaging in primary adrenal lymphoma (PAL). Methods Three male patients with clinically diagnosed PAL, aged 59 to 77 years old, were examined bylSF-FDG PET/CT before histopathologic examination. The SUVmax ratio of tumor to liver (T/L) was calculated on ^18F-FDG PET images. All patients underwent R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy regimens. One patient had serial follow-up ^18F- FDG PET/CT post therapy. Results The final diagnosis of all 3 cases was bilateral diffuse large B-cell lymphoma. The pathologic results of bone marrow biopsy were negative. Case I was in disease remission based on four times of follow-up ^18F-FDG PET/CT. The patient's clinical follow-up was also negative and he was currently alive for more than 19 months. Case 2 was of late stage and suffered from adrenal insufficiency. He died 6 months after the diagnosis. Case 3 ( the eldest patient) was treated with partial excision followed by the chemotherapy. He died of lung infection 12 months after treatment. Conclusion ^18F-FDG PET/CT may be of important value for maximizing patient management and survival for patients with PAL, a rare and highly malignant disease.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2011年第4期237-240,共4页
Chinese Journal of Nuclear Medicine